세계의 피임 제품 시장 : 인사이트, 경쟁 구도 및 시장 예측(2030년)

Contraceptives Market By Type (Male Contraceptives, Female Contraceptives), By Product Type (Contraceptive Drugs [Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives {Patches, Gels, Others}], Contraceptive Devices [Condoms, Diaphragms, Cervical Caps, Vaginal Rings, Intrauterine Devices (IUDs), Subdermal Contraceptive Implants]), by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing awareness about sexually transmitted diseases, rise in government initiatives for population control

Global Contraceptives Market was valued at USD 24.17 billion in 2023, growing at a CAGR of 5.19% during the forecast period from 2024 to 2030 to reach USD 32.61 billion by 2030. The Contraceptives market is witnessing positive growth owing to the increasing awareness about sexually transmitted diseases, rise in government initiatives for population control, upsurge in unintended pregnancies, technological innovations leading to effective contraception, thereby contributing to the growth of the Contraceptives market during the forecast period from 2024-2030.

Contraceptives Market Dynamics:

The contraceptives market is witnessing a growth in product demand owing to various reasons. The increasing awareness about Sexually Transmitted Diseases (STDs) is the key driving factor for the contraceptives market. Sexually Transmitted Diseases (STDs) are the most common infectious disease in most countries, particularly in the age of 15-50 years.

According to the WHO 2019 statistics, more than one million Sexually Transmitted Infections (STIs) are acquired every day worldwide. Their control is important considering the high incidence of acute infections, complications, socioeconomic impact, and their role in increasing human immunodeficiency virus (HIV) transmission. Thus, contraceptive devices such as condoms and diaphragms can prevent the transmission of STIs, therefore, anticipated to contribute to the market growth.

Moreover, the global burden of STIs is attributed to eight major infections, including syphilis, gonorrhea, chlamydia, and human papillomavirus (HPV), among several others. The danger in these infections lies in their ability to persist without always presenting symptoms as well as their high likelihood of transforming into other, more deadly diseases.

To prevent STD transmission several programs such as the United States Agency for International Development (USAID) funded programs provide awareness of sexually transmitted diseases in developing countries. These programs work to increase access to condoms and increase demand through sex education and evidence-based behavior change programs. Thus, rising awareness through awareness campaigns is likely to surge the demand of devices in the contraceptives market.

Therefore, considering the advantages associated with the prevention of STDs with the use of contraceptives, the category is expected to account for a significant market share in the global contraceptives market.

Moreover, another key factor responsible for the increasing demand for contraceptives is the rising focus of governments and international organizations on popularizing population control, which is expected to drive the demand for contraceptives during the forecast period. For instance, keeping in line with the sustainable development goals for 2030 (SDG 2030) put forth by the United Nations, the Family Planning 2030 program aims at achieving voluntary modern contraceptive use, strengthening supply chains so that contraceptives reach those who need them, ensuring that family planning services and supplies have sustained funding support, and improving the quality of care in family planning service.

However, side effects associated with contraceptives and stringent regulations for IUDs, Vaginal Rings, and others may be certain limiting factors to the Contraceptives market growth.

The spread of the COVID-19 infection impacted the growth of the contraceptives market. To contain the spread of COVID infections, most governments are introducing lockdown and social distancing policies to limit transmission and save human lives from novel coronavirus. COVID-19 did not impact women's ability to use contraception, as distribution and availability of contraceptives were fulfilled by local players available in the region through pharmacies or governmental agencies.

Therefore, it is observed that only the supply chain disruptions have impacted the contraceptives market a bit. Moreover, with a wide vaccination drive, the market is expected to grow at its full potential now and in coming years.

Contraceptives Market Segment Analysis:

Contraceptives Market By Type (Male Contraceptives, Female Contraceptives), By Product Type (Contraceptive Drugs [Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives {Patches, Gels, Others}], Contraceptive Devices [Condoms, Diaphragms, Cervical Caps, Vaginal Rings, Intrauterine Devices (IUDs), Subdermal Contraceptive Implants]), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the Product Type segment of the Contraceptives market, Patches are estimated to hold a higher share in the Contraceptives market during the forecast period (2024-2030). This can be attributed to the specific features associated with these Contraceptives.

The wide acceptability of these patches is owing to the factors such as their efficacy in preventing pregnancies, increasing awareness among the population, women finding it difficult to remember taking a pill every day, females having difficulty in swallowing pills, low cost, thereby augmenting for the category growth.

As per NHS UK 2022, the patch is more than 99% effective at preventing pregnancy when used correctly. Moreover, these patches are still effective if the person is sick (vomit) or has diarrhea. They can also be worn in the bath, swimming, and while playing sports. Also, rising regulatory approval is another factor that will upsurge the growth of the overall Contraceptives market.

For instance, in February 2020, the US Food and Drug Administration (FDA) approved Agile Therapeutics' levonorgestrel and Ethinyl estradiol transdermal system (Twirla) for contraception in women.

Therefore, considering their wide applications as an affordable option, the patches category is expected to account for a considerable market share in the contraceptives market.

North America is expected to dominate the overall Contraceptives Market:

Among all the regions, North America is expected to account for the largest share of the global contraceptives market.

According to the Centers for Disease Control and Prevention (CDC) (2023), in 2018, approximately 20% of the United States population about one in five people were suffering from sexually transmitted infection (STI) on any given day. Owing to an increase in the rising prevalence of sexually transmitted diseases, there will be an increase in the demand for contraceptives for preventing sexually transmitted infections, leading to an overall spur in the contraceptives market growth.

An increase in unintended pregnancies also leads to a rise in the need for contraceptives, thereby causing an increase in the overall market growth of contraceptives. For instance, as per the Office of Disease Prevention and Health Promotion (2023), in 2020, almost half (45%) of the 6.1 million annual pregnancies in the United States were found to be unintended.

In addition, rising cases of abortion among people in the United States will also lead to a rise in the demand for oral contraceptives, leading to an overall increase in the growth of the contraceptives market.

Moreover, on April 19, 2022, the United States Food and Drug Administration (FDA) approved a novel contraceptive pill, a combination of drospirenone and estetrol tablet, to prevent pregnancy the first combination pill containing naturally occurring estrogen.

Hence, all the above-mentioned factors are likely to contribute to the growth of the contraceptives market during the forecast period.

Contraceptives Market Key Players:

Some of the key market players operating in the Contraceptives market include Teva Pharmaceutical Industries Ltd, TherapeuticsMD, Inc., AbbVie Inc., Bayer AG, The Cooper Companies Inc., FemCap Inc, Veru Inc., Meril Life Sciences Pvt. Ltd., Pregna International Limited., Reckitt Benckiser Group PLC., Viatris Inc., EUROGINE, S.L, Gedeon Richter Plc., Agile Therapeutics., Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Shanghai Dahua Pharmaceutical Co., Ltd., Pfizer Inc., Contech Devices Private Limited, Cupid Limited, and others.

Recent Developmental Activities in the Contraceptives Market:

In October 2022, Bayer and the US biotech company Dare Bioscience collaborated to develop a hormone-free monthly contraceptive. The device is a ring that is inserted into the vagina, providing contraception over three weeks without any action required by the user around the time of intercourse.

In April 2022, the FDA approved Nextstellis by Mayne Pharma, a combination of drospirenone and estetrol tablets to prevent pregnancy. The first combination pill contains naturally occurring estrogen.

Key Takeaways from the Contraceptives Market Report Study

• Market size analysis for current Contraceptives market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Contraceptives market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global Contraceptives market.
• Various opportunities available for the other competitor in the Contraceptives market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current Contraceptives market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Contraceptives market growth in the coming future?

Target Audience who can be benefited from this Contraceptives Market Report Study

• Contraceptives products providers
• Research organizations and consulting companies
• Contraceptives-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Contraceptives
• Various End-users who want to know more about the Contraceptives market and latest technological developments in the Contraceptives market.

Frequently Asked Questions for the Contraceptives Market:

1. What are Contraceptives?

Contraception methods or Contraceptives are products that help form either physical or chemical barriers against the fusion of gametes or prevent the implantation of the fertilized egg from taking place.

2. What is the market for Global Contraceptives?

Global Contraceptives Market was valued at USD 24.17 billion in 2023, growing at a CAGR of 5.19% during the forecast period from 2024 to 2030 to reach USD 32.61 billion by 2030.

3. What are the drivers for the Global Contraceptives Market?

The Contraceptives market is witnessing positive market growth owing to the increasing awareness about sexually transmitted diseases, rise in government initiatives for population control, upsurge in unintended pregnancies, and technological innovations leading to effective contraception is thereby contributing to the growth of the Contraceptives market.

4. Who are the key players operating in the Global Contraceptives Market?

Some of the key market players operating in the Contraceptives market include Teva Pharmaceutical Industries Ltd, TherapeuticsMD, Inc., AbbVie Inc., Bayer AG, The Cooper Companies Inc., FemCap Inc, Veru Inc., Meril Life Sciences Pvt. Ltd., Pregna International Limited., Reckitt Benckiser Group PLC., Viatris Inc., EUROGINE, S.L, Gedeon Richter Plc., Agile Therapeutics., Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Shanghai Dahua Pharmaceutical Co., Ltd., Pfizer Inc., Contech Devices Private Limited, Cupid Limited, and others.

5. Which region has the highest share in Contraceptives Market?

North America is expected to hold the highest share of the revenue in the Contraceptives market during the forecast period. Due to an increase in the rising prevalence of sexually transmitted diseases, an increase in unintended pregnancies among other factors leads to a rise in the need for contraceptives, thereby causing an increase in the overall market growth of Contraceptives, which are expected to aid in the growth of the North America contraceptives market.

Table of Contents

1.Contraceptives Market Report Introduction

2.Contraceptives Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory and Patent Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Contraceptives Market Key Factors Analysis

• 4.1. Contraceptives Market Drivers
  • 4.1.1. The Increasing Awareness of Sexually Transmitted Diseases
  • 4.1.2. The rise in Government Initiatives For Population Control
  • 4.1.3. Upsurge in Unintended Pregnancies
  • 4.1.4. Technological Innovations Leading To Effective Contraception
• 4.2. Contraceptives Market Restraints and Challenges
  • 4.2.1. Side Effects Associated with Contraceptives
  • 4.2.2. Stringent Regulatory for IUDs, Vaginal Rings, and Others
• 4.3. Contraceptives Market Opportunities
  • 4.3.1. Growth Opportunities in Emerging Countries Owing to Rising Awareness
  • 4.3.2. Rising Need to Develop Contraceptives for Men

5. Contraceptives Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Contraceptives Market

7. Contraceptives Market Layout

• 7.1. By Type
  • 7.1.1. Male Contraceptives
  • 7.1.2. Female Contraceptives
• 7.2. By Product Type
  • 7.2.1. Contraceptive Drugs
    • 7.2.1.1. Oral Contraceptive Pills
    • 7.2.1.2. Injectable Contraceptives
    • 7.2.1.3. Topical Contraceptives
    • 7.2.1.3.1. Patches
    • 7.2.1.3.2. Gels
    • 7.2.1.3.3. Others
  • 7.2.2. Contraceptive Devices
    • 7.2.2.1. Condoms
    • 7.2.2.2. Diaphragms
    • 7.2.2.3. Cervical Caps
    • 7.2.2.4. Vaginal Rings
    • 7.2.2.5. Intrauterine Devices (IUDs)
    • 7.2.2.6. Subdermal Contraceptive Implants
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. North America Contraceptives Market, by Country
    • 7.3.1.1.1. United States
    • 7.3.1.1.2. Canada
    • 7.3.1.1.3. Mexico
  • 7.3.2. Europe
    • 7.3.2.1. Europe Contraceptives Market, by Country
    • 7.3.2.1.1. France
    • 7.3.2.1.2. Germany
    • 7.3.2.1.3. United Kingdom
    • 7.3.2.1.4. Italy
    • 7.3.2.1.5. Spain
    • 7.3.2.1.6. Russia
    • 7.3.2.1.7. Rest of Europe
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. Asia-Pacific Contraceptives Market, by Country
    • 7.3.3.1.1. China
    • 7.3.3.1.2. Japan
    • 7.3.3.1.3. India
    • 7.3.3.1.4. Australia
    • 7.3.3.1.5. South Korea
    • 7.3.3.1.6. Rest of Asia Pacific
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. RoW Contraceptives Market, by Region
    • 7.3.4.1.1. Middle East
    • 7.3.4.1.2. Africa
    • 7.3.4.1.3. South America

8. Contraceptives Market Global Company Share Analysis - Key 3-5 Companies

9. Contraceptives Market Company and Product Profiles

• 9.1. Teva Pharmaceutical Industries Ltd
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. TherapeuticsMD, Inc.
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. AbbVie Inc.
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Bayer AG
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. The Cooper Companies Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. FemCap Inc
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Veru Inc.
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Meril Life Sciences Pvt. Ltd.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Pregna International Limited.
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Reckitt Benckiser Group PLC.
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Viatris Inc.
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. EUROGINE, S.L
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Gedeon Richter Plc.
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Agile Therapeutics.
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Evofem Biosciences, Inc.
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. Amneal Pharmaceuticals LLC.
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Shanghai Dahua Pharmaceutical Co., Ltd.
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Pfizer Inc.
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Contech Devices Private Limited
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. Cupid Limited
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us